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In the original publication, in the Methods
section, Scholl Fungal Nail Treatment is
incorrectly attributed to Bayer Healthcare AG
who is neither the manufacturer nor the market
authorization holder. This should state Scholl
Fungal Nail Treatment, Reckitt Benckiser
Healthcare, UK.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
The online version of the original article can be found
under doi:10.1007/s13555-016-0093-x.
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